胸腹主动脉瘤开窗分支腔内修复术后性别相关结局
该研究分析886例接受开窗分支腔内修复术(FBEVAR)的胸腹主动脉瘤(TAAA)患者,其中女性288例(33%)。女性动脉瘤更广泛、糖尿病更多,但冠心病和既往EVAR史更少,手术时间更长、技术成功率更低;30天结局和1年多数结局无性别差异,但女性瘤囊扩张发生率更高。
要点
- 女性TAAA患者接受FBEVAR时动脉瘤更广泛、糖尿病比例更高,技术成功率更低。
- 女性与男性30天死亡率和1年多数结局相似,但女性瘤囊扩张发生率更高。
- 多变量分析显示性别不是生存的独立预测因素。
核心结论
- 女性接受FBEVAR的动脉瘤更复杂、技术成功率更低,但30天死亡率和1年多数结局与男性相似,仅瘤囊扩张发生率更高。
研究设计与样本
- 分析2013至2019年8项前瞻性、医生发起的研究性器械豁免研究中的886例I至IV型TAAA患者(排除肾旁或近肾动脉瘤)。
- 所有患者均使用Cook定制开窗分支器械或Cook t-Branch现货器械。
- 数据前瞻性收集,经临床事件委员会和/或数据安全监测委员会审核裁定,并接受FDA监管。
主要发现
- 女性288例(33%),动脉瘤更广泛,糖尿病患病率更高(33% vs 26%;P = .043),冠心病患病率更低(33% vs 52%;P < .0001),既往肾下EVAR史更少(7.6% vs 16%;P < .001)。
- 女性手术时间更长(5.0 ± 1.8小时 vs 4.6 ± 1.7小时;P < .001),技术成功率更低(93% vs 98%;P = .002),出院回家比例更低(72% vs 83%;P = .009)。
- 女性与男性在免于I型或III型内漏(91.4% vs 92.0%;P = .64)、免于再干预(81.7% vs 85.3%;P = .10)、靶血管不稳定(87.5% vs 89.2%;P = .31)和生存率(89.6% vs 91.7%;P = .26)方面无差异。
- 女性术后瘤囊扩张发生率更高(12% vs 6.5%;P = .006)。
- 多变量模型调整年龄、动脉瘤范围、动脉瘤大小、急诊手术和肾功能后,性别不是生存的独立预测因素(风险比,0.83;95%CI,0.50-1.37;P = .46)。
临床怎么用
- FBEVAR对女性和男性均安全有效,但女性动脉瘤更复杂、技术成功率更低,应关注女性患者的技术挑战。
- 女性术后瘤囊扩张发生率更高,需加强影像学随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fenestrated-branched endovascular aneurysm repair (FBEVAR) has expanded the treatment of patients with thoracoabdominal aortic aneurysms (TAAAs). Previous studies have demonstrated that women are less likely to be treated with standard infrarenal endovascular aneurysm repair because of anatomic ineligibility and experience greater mortality after both infrarenal and thoracic aortic aneurysm repair. The purpose of the present study was to describe the sex-related outcomes after FBEVAR for treatment of TAAAs. METHODS: The data from 886 patients with extent I to IV TAAAs (excluding pararenal or juxtarenal aneurysms), enrolled in eight prospective, physician-sponsored, investigational device exemption studies from 2013 to 2019, were analyzed. All data were collected prospectively, audited and adjudicated by clinical events committees and/or data safety monitoring boards, and subject to Food and Drug Administration oversight. All the patients had been treated with Cook-manufactured patient-specific FBEVAR devices or the Cook t-Branch off-the-shelf device (Cook Medical, Brisbane, Australia). RESULTS: Of the 886 patients who underwent FBEVAR, 288 (33%) were women. The women had more extensive aneurysms and a greater prevalence of diabetes (33% vs 26%; P = .043) but a lower prevalence of coronary artery disease (33% vs 52%; P < .0001) and previous infrarenal endovascular aneurysm repair (7.6% vs 16%; P < .001). The women had required a longer operative time from incision to surgery end (5.0 ± 1.8 hours vs 4.6 ± 1.7 hours; P < .001), experienced lower technical success (93% vs 98%; P = .002), and were less likely to be discharged to home (72% vs 83%; P = .009). Despite the smaller access vessels, the women did not have an increased incidence of access site complications. Also, the 30-day outcomes were broadly similar between the sexes. At 1 year, no differences were found between the women and men in freedom from type I or III endoleak (91.4% vs 92.0%; P = .64), freedom from reintervention (81.7% vs 85.3%; P = .10), target vessel instability (87.5% vs 89.2%; P = .31), and survival (89.6% vs 91.7%; P = .26). The women had a greater incidence of postoperative sac expansion (12% vs 6.5%; P = .006). Multivariable modeling adjusted for age, aneurysm extent, aneurysm size, urgent procedure, and renal function showed that patient sex was not an independent predictor of survival (hazard ratio, 0.83; 95% confidence interval, 0.50-1.37; P = .46). CONCLUSIONS: Women undergoing FBEVAR demonstrated metrics of increased complexity and had a lower level of technical success, especially those with extensive aneurysms. Compared with the men, the women had similar 30-day mortality and 1-year outcomes, with the exception of an increased incidence of sac expansion. These data have demonstrated that FBEVAR is safe and effective for women and men but that further efforts to improve outcome parity are indicated.
引用
- Edman NI, Schanzer A, Crawford A, et al. Sex-related outcomes after fenestrated-branched endovascular aneurysm repair for thoracoabdominal aortic aneurysms in the U.S. Fenestrated and Branched Aortic Research Consortium. J Vasc Surg. 2021. PMID: 33775747. doi:10.1016/j.jvs.2021.02.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。